Bone Marrow Transplantation - Table of Contents alert Volume 47 Issue 10

TABLE OF CONTENTS Volume 47, Issue 10 (October 2012) In this issue Reviews Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Now accepting original research submissions! Open access option - Competitive turnaround times - Internationally renowned Editorial Board Serving the international community of researchers and physicians with in-depth coverage on all scientific and clinical aspects of bone health and disease. Learn more about preparing your manuscript for submission.   Reviews Top Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT N Reddy and B N Savani Bone Marrow Transplant 2012 47: 1265-1268; advance online publication, October 17, 2011; 10.1038/bmt.2011.204 Abstract | Full Text Between Scylla and Charybdis: antithrombotic therapy in hematopoietic progenitor cell transplant patients T G DeLoughery Bone Marrow Transplant 2012 47: 1269-1273; advance online publication, September 12, 2011; 10.1038/bmt.2011.177 Abstract | Full Text Original Articles Top CONDITIONING REGIMENS Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity A Shimoni, N Shem-Tov, Y Volchek, I Danylesko, R Yerushalmi and A Nagler Bone Marrow Transplant 2012 47: 1274-1282; advance online publication, February 13, 2012; 10.1038/bmt.2012.4 Abstract | Full Text STEM CELL PROCUREMENT Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors M E Horwitz, G Long, P Holman, E Libby, G C Calandra and J R Schriber Bone Marrow Transplant 2012 47: 1283-1286; advance online publication, February 20, 2012; 10.1038/bmt.2012.21 Abstract | Full Text CORD BLOOD STEM CELLS Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen J Sanz, J C H Boluda, C Martín, M González, C Ferrá, D Serrano, C D de Heredia, C Barrenetxea, A M Martinez, C Solano, M A Sanz and G F Sanz on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH) Bone Marrow Transplant 2012 47: 1287-1293; advance online publication, February 13, 2012; 10.1038/bmt.2012.13 Abstract | Full Text PEDIATRIC TRANSPLANTS Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II J Harvey, A Green, J Cornish, C Steward, M Cummins, L Keen, S Culliford, A Poles, L Hunt, P Breslin, Y Li and J Moppett Bone Marrow Transplant 2012 47: 1294-1300; advance online publication, February 20, 2012; 10.1038/bmt.2012.8 Abstract | Full Text Attenuation of resting energy expenditure following hematopoietic SCT in children L J Bechard, H A Feldman, R Venick, K Gura, C Gordon, A Sonis, N Mehta, E C Guinan and C Duggan Bone Marrow Transplant 2012 47: 1301-1306; advance online publication, February 20, 2012; 10.1038/bmt.2012.19 Abstract | Full Text Second allogeneic hematopoietic SCT for relapsed ALL in children M Kato, Y Horikoshi, Y Okamoto, Y Takahashi, D Hasegawa, K Koh, J Takita, M Inoue, H Kigasawa, A Ogawa, Y Sasahara, K Kawa, H Yabe, H Sakamaki, R Suzuki and K Kato Bone Marrow Transplant 2012 47: 1307-1311; advance online publication, February 27, 2012; 10.1038/bmt.2012.29 Abstract | Full Text ALLOGRAFTING Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center W Bensinger, M Rotta, B Storer, T Chauncey, L Holmberg, P Becker, B M Sandmaier, R Storb and D Maloney Bone Marrow Transplant 2012 47: 1312-1317; advance online publication, February 13, 2012; 10.1038/bmt.2012.1 Abstract | Full Text AUTOGRAFTING Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma N Reddy, J P Greer, S Goodman, B Engelhardt, O Oluwole, M H Jagasia and B N Savani Bone Marrow Transplant 2012 47: 1318-1320; advance online publication, February 13, 2012; 10.1038/bmt.2012.10 Abstract | Full Text High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases M Mohr, I Hartig, T Kessler, C Hamisch, S Kliesch, U Krug, T Spieker, M Semik, K Wiebe, G Pühse, L Hertle, R Liersch, C Müller-Tidow, R M Mesters and W E Berdel Bone Marrow Transplant 2012 47: 1321-1325; advance online publication, February 13, 2012; 10.1038/bmt.2012.14 Abstract | Full Text MICROBIAL ISSUES The clinical role of procalcitonin in hematopoietic SCT J Koya, Y Nannya, M Ichikawa and M Kurokawa Bone Marrow Transplant 2012 47: 1326-1331; advance online publication, February 20, 2012; 10.1038/bmt.2012.18 Abstract | Full Text POST-TRANSPLANT EVENTS High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT R Tizon, N Frey, D F Heitjan, K S Tan, S C Goldstein, E O Hexner, A Loren, S M Luger, R Reshef, D Tsai, D Vogl, J Davis, M Vozniak, B Fuchs, E A Stadtmauer and D L Porter Bone Marrow Transplant 2012 47: 1332-1337; advance online publication, February 6, 2012; 10.1038/bmt.2011.260 Abstract | Full Text Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors K Taniguchi, S Yoshihara, E Maruya, K Ikegame, K Kaida, K Hayashi, R Kato, T Inoue, T Fujioka, H Tamaki, M Okada, T Onuma, N Fujii, Y Kusunoki, T Soma, H Saji and H Ogawa Bone Marrow Transplant 2012 47: 1338-1342; advance online publication, February 27, 2012; 10.1038/bmt.2012.28 Abstract | Full Text Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning P Barba, R Martino, J A Perez-Simón, F Fernández-Avilés, J L Piñana, D Valcárcel, I Campos-Varela, L Lopez-Anglada, M Rovira, S Novelli, L Lopez-Corral, E Carreras and J Sierra Bone Marrow Transplant 2012 47: 1343-1349; advance online publication, March 5, 2012; 10.1038/bmt.2012.25 Abstract | Full Text GRAFT-VERSUS-HOST DISEASE Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial M H Jagasia, R Abonour, G D Long, B J Bolwell, G G Laport, T B Shore, S Durrant, J Szer, M-G Chen, R Lizambri and E K Waller Bone Marrow Transplant 2012 47: 1350-1355; advance online publication, February 13, 2012; 10.1038/bmt.2011.261 Abstract | Full Text Anti-host isohemagglutinin production is associated with a higher risk of acute GVHD in ABO-incompatible transplantation A Igarashi, K Kakihana, K Haraguchi, J Aoki, T Kobayashi, Y Okuyama, K Ohashi and H Sakamaki Bone Marrow Transplant 2012 47: 1356-1360; advance online publication, March 5, 2012; 10.1038/bmt.2012.32 Abstract | Full Text QUALITY OF LIFE The psychosocial impact of haematopoietic SCT on sibling donors B Pillay, S J Lee, L Katona, S De Bono, N Warren, J Fletcher and S Burney Bone Marrow Transplant 2012 47: 1361-1365; advance online publication, February 20, 2012; 10.1038/bmt.2012.22 Abstract | Full Text Letters to the Editor Top Surgical resection as definitive treatment for refractory GVHD of the colon R F Cornell, J Palmer, R Komorowski and W R Drobyski Bone Marrow Transplant 2012 47: 1366-1367; advance online publication, February 13, 2012; 10.1038/bmt.2012.15 Full Text Successful treatment of a refractory skin ulcer in chronic cutaneous GvHD after allogeneic HSCT with split-thickness skin allografting from the stem cell donor J Ammer, L Prantl, B Holler, K Landfried, D Wolff, S Karrer, R Andreesen and E Holler Bone Marrow Transplant 2012 47: 1368-1369; advance online publication, February 20, 2012; 10.1038/bmt.2012.16 Full Text Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles R El Fakih, G A Obi, A Scholoff, G Carrum and R T Kamble Bone Marrow Transplant 2012 47: 1370-1371; advance online publication, February 13, 2012; 10.1038/bmt.2012.17 Full Text Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ≤0.5 × 106 CD34+ cells/kg at first mobilization Q A Hill, R Pearce and G Cook Bone Marrow Transplant 2012 47: 1372-1373; advance online publication, February 20, 2012; 10.1038/bmt.2012.20 Full Text Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT F Lemonnier, E Rivaud, H Neveu, E Catherinot, F Suarez, N Dhedin and L-J Couderc Bone Marrow Transplant 2012 47: 1374; advance online publication, February 27, 2012; 10.1038/bmt.2012.23 Full Text Serial assessment of toxicity after hematopoietic SCT can discern kinetics of transplant-related organ injury and patterns of recovery A Chou, M Guo, J Tay, H Atkins, I Bence-Bruckler, M Sabloff, L Huebsch and D Allan Bone Marrow Transplant 2012 47: 1375-1376; advance online publication, March 5, 2012; 10.1038/bmt.2012.27 Full Text No evidence for the reversal of adrenal failure after hematopoietic cell transplantation in X-linked adrenoleukodystrophy A Petryk, L E Polgreen, S Chahla, W Miller and P J Orchard Bone Marrow Transplant 2012 47: 1377-1378; advance online publication, March 5, 2012; 10.1038/bmt.2012.33 Full Text Posaconazole is not superior to itraconazole for fungal prophylaxis in allogeneic blood and marrow transplantation S B Mossad Bone Marrow Transplant 2012 47: 1379; advance online publication, March 5, 2012; 10.1038/bmt.2012.34 Full Text Reply to SB Mossad I Sánchez-Ortega, M Encuentra and R F Duarte Bone Marrow Transplant 2012 47: 1380; advance online publication, March 5, 2012; 10.1038/bmt.2012.35 Full Text Posterior reversible encephalopathy syndrome in a child with post-transplant HHV-6B encephalitis Y Kawamura, M Ohashi, H Asahito, Y Takahashi, S Kojima and T Yoshikawa Bone Marrow Transplant 2012 47: 1381-1382; advance online publication, March 5, 2012; 10.1038/bmt.2012.42 Full Text Putting caution in TEAM: high-dose chemotherapy with autologous HSCT for primary central nervous system lymphoma R L Tombleson, M R Green and K M Fancher Bone Marrow Transplant 2012 47: 1383-1384; advance online publication, March 19, 2012; 10.1038/bmt.2012.48 Full Text Advertisement Online-only personal subscriptions now available For only 49 USD/29 GBP/29 EUR to selected journals Subscribe now!   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Bone Marrow Transplantation. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.